Forecast Period | 2025-2029 |
Market Size (2023) | USD 145.48 Million |
Market Size (2029) | USD 261.84 Million |
CAGR (2024-2029) | 10.25% |
Fastest Growing Segment | 16S rRNA Sequencing |
Largest Market | North America |
Market Overview
Global Microbiome
Diagnostics Market was valued at USD 145.48 Million in 2023 and is anticipated
to project impressive growth in the forecast period with a CAGR of 10.25%
through 2029. The global microbiome diagnostics market has experienced robust
growth in recent years, fueled by breakthroughs in microbiome research,
heightened awareness of personalized medicine, and the rising demand for early
disease detection. Microbiome diagnostics involves advanced techniques to
analyze the composition of microbiota bacteria, fungi, and viruses within the
human body to diagnose and monitor health conditions. This sector is showing
significant promise across critical areas such as gastrointestinal disorders,
metabolic diseases, oncology, and infectious diseases. The microbiome
diagnostics market is positioned for substantial expansion over the next
decade. Leading industry players are actively pursuing strategic partnerships,
mergers, and acquisitions to strengthen their competitive edge and drive
innovation. The integration of AI-powered analytics into diagnostic platforms
is expected to enhance precision and expand clinical applications, especially
as consumer interest in preventive healthcare grows. Furthermore, as the cost
of microbiome diagnostics decreases and regulatory frameworks become more
streamlined, adoption is expected to accelerate across both developed and
emerging markets.
This projected
growth is further supported by increasing investment in research and
development, alongside efforts to improve access to these diagnostic tools.
Companies that can navigate regulatory complexities, reduce costs, and
demonstrate clinical utility will be well-positioned to capitalize on this
rapidly evolving market.
Key Market Drivers
Rising Prevalence of Chronic
Diseases
The
rising prevalence of chronic diseases is a major driver of growth in the global
microbiome diagnostics market. Chronic conditions such as diabetes, cancer,
cardiovascular diseases, obesity, and autoimmune disorders are increasing
worldwide, putting immense pressure on healthcare systems to develop more
effective diagnostic and treatment tools. Microbiome diagnostics plays a
crucial role in addressing this challenge by offering innovative solutions that
enable early detection, personalized disease management, and prevention. Research
has established a strong connection between microbiome dysbiosis (an imbalance
in the microbial communities in the human body) and the onset or progression of
many chronic diseases. Conditions like diabetes and obesity have been
associated with changes in gut microbiota, where harmful bacteria can influence
metabolic processes, inflammation, and immune responses. Similarly, imbalances
in the microbiome are linked to inflammatory bowel diseases (IBD),
cardiovascular issues, and even some types of cancer, such as colorectal
cancer. As these connections between microbiome health and chronic disease
become clearer, the demand for diagnostic tools that can assess the microbiome
has surged. Healthcare providers and researchers are increasingly turning to
microbiome diagnostics to monitor microbial balance, predict disease risks, and
guide therapeutic decisions. This demand is accelerating the development of new
diagnostic solutions and driving market growth.
Early
detection is critical in managing chronic diseases, especially when it comes to
conditions like cancer, cardiovascular diseases, and autoimmune disorders.
Microbiome diagnostics provides a non-invasive, advanced method to detect early
changes in microbial composition that may signal the onset of a disease before
clinical symptoms appear. For instance, early shifts in gut microbiota can be
indicative of type 2 diabetes development or the onset of inflammatory
conditions. The ability to detect these early microbial imbalances enables
healthcare providers to implement timely interventions, potentially preventing
the disease from advancing to a more severe stage. This aspect of early
detection has spurred interest in microbiome diagnostics across healthcare
systems, as it aligns with the growing emphasis on preventive healthcare. The
potential to reduce healthcare costs by diagnosing and managing chronic
conditions early is another driver for the increasing adoption of microbiome
diagnostics. Microbiome diagnostics is becoming integral to the field of
personalized medicine, particularly in chronic disease management. Chronic
diseases often vary in how they manifest and progress from one patient to
another, necessitating personalized treatment approaches. Microbiome analysis
allows healthcare providers to understand the unique microbial environment of
each patient, tailoring treatment plans accordingly. For example, in the
management of gastrointestinal diseases like IBD or irritable bowel syndrome
(IBS), microbiome diagnostics can reveal specific bacterial imbalances, helping
clinicians customize probiotic or dietary interventions. In cancer treatment,
microbiome diagnostics are being explored to predict patient responses to
immunotherapies, as microbiota can influence how well a patient responds to
certain treatments. This shift toward personalized medicine is driving
healthcare providers to incorporate microbiome diagnostics into chronic disease
treatment protocols, leading to increased demand and market growth.
Pharmaceutical and biotech companies are also leveraging microbiome insights to
develop more effective drugs tailored to the microbiome profiles of different
patient groups, further expanding the market.
In
addition to diagnostics, the microbiome is increasingly used to monitor disease
progression and patient response to therapies. For chronic conditions like
diabetes and obesity, regular monitoring of the microbiota provides ongoing
insights into how well a patient is managing their condition. For instance,
microbiome analysis can reveal whether dietary changes or medications are
having the desired effect on improving gut health and metabolic function. In
the context of cancer treatment, ongoing microbiome diagnostics can help assess
how patients are responding to chemotherapy or immunotherapy, allowing for
real-time adjustments in treatment plans. This dynamic monitoring capability is
highly valuable in chronic disease management, where patient conditions may
evolve over time and require adaptive therapeutic strategies. The growing use
of microbiome diagnostics for monitoring has led to an increase in repeat
testing, further driving the market. As the healthcare industry continues to
prioritize long-term disease management, the demand for diagnostics that can
provide continuous insights into patient health, such as microbiome tests, is
expected to grow. The global healthcare system is facing an increasing burden
from chronic diseases. According to the World Health Organization (WHO),
chronic diseases account for approximately 71% of all deaths worldwide. The
rising incidence of these diseases is leading to higher healthcare costs,
including long-term treatment, hospitalizations, and management of
complications. This has prompted a shift toward more cost-effective,
preventative approaches, where microbiome diagnostics plays a key role. By
providing actionable insights into disease risk and enabling early
interventions, microbiome diagnostics offers the potential to reduce the
overall healthcare burden associated with chronic disease management. This
aligns with the growing emphasis on preventive care, value-based healthcare,
and reducing healthcare costs. As a result, governments and healthcare
providers are increasingly incorporating microbiome diagnostics into public
health strategies, contributing to its market growth.
Advances in Microbiome
Research and Technology
Advances
in microbiome research and technology have been instrumental in driving the
growth of the global microbiome diagnostics market. Innovations in scientific
understanding, coupled with cutting-edge technologies, have transformed how
microbiota is analyzed, enabling more precise and actionable diagnostic
insights. These developments are not only expanding the scope of microbiome
diagnostics but also accelerating its adoption in clinical practice. One of the
most significant technological advancements driving the microbiome diagnostics
market is next-generation sequencing (NGS). NGS technologies allow for
comprehensive and high-throughput analysis of microbial genomes, offering
unparalleled accuracy and detail in microbiome profiling. Unlike traditional
methods that could only identify a limited range of microbial species, NGS
provides a holistic view of the entire microbial ecosystem within the body,
including bacteria, viruses, fungi, and archaea. Deeper insights into microbial
diversity, composition, and interactions, which play a critical role in health
and disease. Rapid and scalable testing, allowing researchers and clinicians to
analyze large patient populations efficiently. These capabilities are driving
the development of more sophisticated and personalized diagnostic tests,
fueling demand across both research institutions and healthcare providers.
Companies leveraging NGS platforms are at the forefront of offering advanced
microbiome diagnostics, driving further market expansion. Advances in
bioinformatics and data analytics have been essential in translating the vast
amount of raw data generated by microbiome research into meaningful clinical
insights. Analyzing microbial genomes involves processing massive datasets, and
bioinformatics tools are critical for interpreting this information
effectively.
Bioinformatics algorithms can detect subtle
microbial changes and patterns that may be linked to specific diseases. Automated
analysis powered by machine learning algorithms reduces the time needed to
interpret complex microbial data. Bioinformatics enables the identification of
unique microbial signatures for each patient, supporting the growing trend
toward personalized medicine.
Bioinformatics
advancements are not only improving the quality of microbiome diagnostics but
also making them more scalable and accessible to a broader market. As
healthcare providers increasingly seek data-driven insights, companies
specializing in microbiome diagnostics that incorporate robust bioinformatics
platforms are experiencing strong demand, thus boosting market growth. The
detailed insights provided by microbiome research are opening up new
opportunities for targeted diagnostics and therapeutics. With a better
understanding of the relationship between microbiota and disease, researchers
are developing diagnostic tests that focus on specific bacterial strains or
microbial imbalances associated with various health conditions.
Conditions
like inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are
now being linked to specific microbial imbalances. Diagnostic tests targeting
these imbalances are enabling more accurate disease classification and
treatment planning. Microbiome research has revealed that microbial communities
can influence cancer development and patient responses to immunotherapy.
Diagnostic tools designed to assess the microbiome’s impact on cancer
progression are creating new pathways for early detection and personalized
treatment. Microbiome diagnostics can detect harmful pathogens or microbial
shifts that lead to infections, allowing for more effective and timely
interventions. The ability to create highly targeted diagnostics based on
individual microbial profiles is driving the development of precision medicine,
which is a rapidly growing sector in healthcare. Companies that can offer
specific, actionable microbiome diagnostics are well-positioned to capitalize
on this growing demand, driving both product innovation and market expansion.
One
of the key innovations stemming from microbiome research is the development of
non-invasive diagnostic tools, which has significantly broadened the
accessibility and usability of microbiome diagnostics. Traditional diagnostic
methods often involve invasive procedures like biopsies, but advances in
microbiome research have enabled the use of less invasive techniques, such as
stool, saliva, and blood samples, to analyze microbial compositions.
Non-invasive
sampling is far more comfortable for patients, making it easier to conduct
repeat tests and attract wider patient acceptance. The ease of collecting
non-invasive samples has made microbiome diagnostics more feasible for both
healthcare providers and patients, promoting wider usage. Non-invasive
diagnostics tend to be less expensive than invasive alternatives, broadening
their appeal in cost-sensitive markets.
The
ability to offer accurate, non-invasive diagnostic solutions is enabling
companies to penetrate diverse segments of the healthcare market, from wellness
and preventive care to chronic disease management, driving significant growth.
Growing Focus on Personalized
Medicine
The
growing focus on personalized medicine is a major catalyst driving the
expansion of the global microbiome diagnostics market. Personalized medicine,
also known as precision medicine, is an approach that tailors healthcare
solutions to individual patients based on their unique genetic, environmental,
and lifestyle factors. As research continues to reveal the pivotal role of the
microbiome in health and disease, microbiome diagnostics is emerging as a key
enabler of personalized healthcare. This is transforming the way diseases are
diagnosed, treated, and prevented, creating significant growth opportunities
for the microbiome diagnostics market.
Personalized
medicine seeks to move away from the traditional “one-size-fits-all” approach
to diagnosis and treatment, offering more individualized care. Microbiome
diagnostics is central to this shift because it allows for the precise analysis
of a patient’s unique microbial profile—the combination of bacteria, viruses,
fungi, and other microorganisms that live in the human body, primarily in the
gut. Variations in these microbial communities can significantly influence a
person’s health, response to treatments, and susceptibility to diseases. Identify
specific disease markers unique to a patient’s microbiome, improving the
accuracy of diagnosis. Detect early signs of disease that are often missed by
traditional diagnostic methods. Provide insights into disease progression and
individual responses to therapies. As healthcare moves toward more precise
diagnostics, the ability to offer personalized assessments based on microbiome
profiles is becoming a valuable tool in clinical practice. This growing demand
for individualized diagnostic insights is contributing to the rapid expansion
of the microbiome diagnostics market.
The
ability to tailor treatments based on a patient’s unique biological makeup is
one of the primary goals of personalized medicine. Microbiome diagnostics plays
a crucial role in achieving this by providing critical insights into how
individual patients respond to different therapies. Studies have shown that the composition of the
gut microbiome can influence how patients respond to immunotherapy, a treatment
that uses the immune system to fight cancer. Microbiome diagnostics helps
identify patients who are more likely to benefit from such treatments, enabling
clinicians to make more informed decisions about therapy options. Conditions
such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)
have been linked to imbalances in gut microbiota. Microbiome diagnostics can
pinpoint specific microbial shifts, allowing for targeted treatments such as
personalized probiotics, dietary changes, or specific medications that address
the root cause of the microbial imbalance. The gut microbiome has a direct
impact on metabolism, and microbial imbalances are linked to conditions like
obesity and diabetes. Microbiome diagnostics can help personalize treatment
strategies, such as adjusting dietary interventions or selecting medications
that optimize a patient’s metabolic response. This ability to create customized
treatment plans based on a patient’s microbiome is accelerating the demand for
diagnostic tools that offer these tailored insights. As personalized medicine
becomes more integral to healthcare, microbiome diagnostics will increasingly
be incorporated into therapeutic decision-making, driving market growth.
One
of the key benefits of personalized medicine is its emphasis on preventive
care—identifying and addressing potential health issues before they develop
into more serious conditions. Microbiome diagnostics aligns perfectly with this
approach, as it allows for the detection of microbial imbalances that can serve
as early warning signs for diseases like diabetes, cardiovascular diseases, and
autoimmune disorders. Changes in gut microbiota may indicate a higher risk of
developing metabolic disorders, allowing patients and healthcare providers to
take preventive measures, such as lifestyle changes or dietary adjustments, to
mitigate the risk. Microbiome diagnostics can help assess cancer risk by
identifying microbial patterns associated with certain types of cancer, such as
colorectal cancer, enabling earlier interventions. The analysis of the
microbiome may also reveal susceptibility to infections or inflammatory
conditions, offering an opportunity to prevent illness before it escalates. The
ability to offer such personalized, preventive insights is highly valuable,
particularly as healthcare systems prioritize cost-effective, proactive
approaches to disease management. As a result, the demand for microbiome
diagnostics as a tool for early detection and prevention is growing,
contributing to the expansion of the market.
Download Free Sample Report
Key Market Challenges
Regulatory Hurdles
The
regulatory landscape for microbiome diagnostics is complex and often
inconsistent across different regions. Regulatory agencies such as the U.S.
Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are
still developing frameworks specific to microbiome-related products.
There
is currently no universally accepted standard for microbiome testing. Different
companies may use varying methodologies, which complicates the validation
process. This inconsistency can hinder the establishment of reliable diagnostic
benchmarks, making it difficult for regulatory bodies to assess the efficacy
and safety of microbiome diagnostics. The pathways for obtaining regulatory
approvals can be lengthy and resource-intensive. Companies may face delays in
bringing their products to market due to prolonged review processes and the
need to provide extensive clinical evidence of safety and efficacy. This can
deter investment in microbiome diagnostics and slow the pace of innovation. Regulatory
guidelines are continuously evolving as new scientific insights emerge.
Companies may find it challenging to keep pace with changing regulations,
potentially leading to increased compliance costs and operational disruptions.
This uncertainty can also deter potential investors who are wary of navigating
a shifting regulatory environment.
The
lack of clear regulatory pathways and the potential for prolonged approval
processes can significantly restrict the growth of the microbiome diagnostics
market, as companies may hesitate to invest in product development without a
clear understanding of regulatory requirements.
Scientific Uncertainties and
Complexity
Despite
the rapid advancements in microbiome research, significant scientific
uncertainties persist that can impede market growth. These uncertainties arise
from the complex nature of the human microbiome and the challenges associated
with interpreting its role in health and disease.
The
human microbiome is highly individualistic, influenced by a multitude of
factors such as genetics, diet, environment, and lifestyle. This variability
can complicate the interpretation of microbiome data and make it challenging to
establish clear associations between specific microbial profiles and health
outcomes. Consequently, diagnostic tests may lack the specificity and
sensitivity needed for reliable clinical applications. Determining whether
specific microbial changes directly contribute to health issues or are merely
correlated with them remains a significant challenge. The complexity of
microbial interactions within the ecosystem complicates the understanding of
causative relationships. This uncertainty may lead to skepticism among
healthcare providers and patients regarding the clinical utility of microbiome
diagnostics, limiting their acceptance and adoption. The dynamic nature of the
microbiome necessitates long-term studies to better understand its impact on
health and disease. However, such studies are often resource-intensive and
time-consuming, which can slow down the generation of robust clinical evidence
needed to support microbiome diagnostics. Without strong evidence, gaining
traction in the clinical landscape becomes difficult.
The
scientific uncertainties surrounding microbiome research can create barriers to
the adoption of microbiome diagnostics. These challenges can hinder confidence
in diagnostic products and lead to reluctance among healthcare providers to
integrate them into clinical practice.
Key Market Trends
Increasing Integration of
Artificial Intelligence and Machine Learning
The
integration of artificial intelligence (AI) and machine learning (ML) into
microbiome diagnostics is a transformative trend that is set to redefine the
landscape of microbiome research and analysis. AI and ML technologies are
becoming increasingly essential for processing and interpreting the vast
amounts of data generated from microbiome studies. This trend is characterized
by several key developments:
AI
algorithms can analyze complex microbiome datasets, identifying patterns and
correlations that may not be readily apparent through traditional analytical
methods. By leveraging machine learning, researchers can develop predictive
models that associate specific microbial profiles with health outcomes,
improving the accuracy of diagnostics. As AI-driven analytics gain traction,
healthcare providers will increasingly utilize these insights to offer
personalized treatment plans based on individual microbiome profiles. This
capability will facilitate more effective interventions tailored to a patient’s
unique microbial composition, further advancing the field of personalized
medicine. The implementation of AI and ML can streamline the diagnostic
process, reducing the time required for data analysis and interpretation.
Automated workflows can enhance laboratory efficiency, enabling healthcare
providers to deliver faster results and improve patient care.
As
AI and ML technologies continue to evolve, their integration into microbiome
diagnostics will drive innovation, enhance the accuracy of analyses, and create
new opportunities for personalized healthcare solutions, ultimately propelling
market growth.
Expanding Applications Beyond
Gastrointestinal Health
While
microbiome diagnostics has traditionally focused on gastrointestinal health,
there is a growing trend towards expanding its applications into various
therapeutic areas. This diversification is opening new avenues for growth
within the market:
Emerging
research indicates a strong link between the microbiome and cancer progression,
as well as responses to treatment. Microbiome diagnostics are increasingly
being developed to identify microbial signatures associated with different
cancer types, facilitating earlier detection and more personalized treatment
strategies. The relationship between the microbiome and metabolic conditions,
such as obesity and diabetes, is gaining attention. Diagnostics that can assess
microbial influences on metabolism are being explored to develop targeted
dietary interventions and personalized management plans. There is a growing
body of evidence suggesting that the gut microbiome may impact neurological and
mental health conditions, such as depression and anxiety. Microbiome
diagnostics are being investigated for their potential to inform treatment
decisions in these areas, broadening the scope of applications and attracting
interest from a wider range of healthcare providers.
The
expansion of microbiome diagnostics into these diverse applications will
enhance market growth by tapping into new patient populations, encouraging
further research and development, and increasing the overall utility of
microbiome-based solutions in clinical practice.
Segmental Insights
Technology Insights
Based
on the category of Technology, the 16S rRNA sequencing segment emerged as the
dominant in the global market for Microbiome Diagnostics in 2023. 16S rRNA
sequencing is one of the most widely used methods for studying microbial
communities. This technique focuses on amplifying and sequencing a specific
region of the 16S ribosomal RNA gene, which is conserved among bacteria but
contains variable regions that provide insights into microbial diversity.
The
primary reasons for the dominance of 16S rRNA sequencing in the microbiome
diagnostics market is its relative simplicity and cost-effectiveness compared
to other techniques. The method requires less computational power and can
produce reliable results quickly, making it accessible for a broader range of
research and clinical applications. This technique has been extensively
validated and standardized, resulting in a wealth of existing data that
researchers can leverage. The established protocols enhance confidence among
researchers and clinicians, contributing to its continued popularity. 16S rRNA
sequencing is particularly effective for identifying bacterial diversity in
various environments, including human gut microbiomes, soil, and aquatic
systems. This versatility drives its adoption across multiple sectors, from
clinical diagnostics to environmental studies. These factors collectively
contribute to the growth of this segment.
Download Free Sample Report
Regional Insights
North
America emerged as the dominant in the global Microbiome Diagnostics market in
2023, holding the largest market share in terms of value. The presence of
world-renowned universities and research centers, such as the National
Institutes of Health (NIH) and various university-led microbiome initiatives,
fosters innovation. These institutions attract significant funding and talent,
facilitating groundbreaking research that drives the development of novel
diagnostic technologies. The region benefits from a collaborative environment
among academia, industry, and government agencies. Public-private partnerships
and consortia focused on microbiome research promote the exchange of knowledge
and resources, accelerating the translation of research findings into practical
diagnostic applications. North America is home to a significant number of
biotechnology firms specializing in microbiome diagnostics. Increased
investment from venture capitalists and government grants supports the
commercialization of innovative technologies, further strengthening the
region's position in the market.
The
regulatory framework in North America is generally supportive of innovation in
microbiome diagnostics, providing a clear pathway for the development and
approval of new diagnostic products. Agencies such as the U.S. Food and Drug
Administration (FDA) and Health Canada have established guidelines for
microbiome-based products. These clear regulations provide companies with a
roadmap for compliance, facilitating faster market entry for new diagnostic
tests. North American regulatory agencies have shown a willingness to adapt
their frameworks to accommodate the unique challenges posed by microbiome
diagnostics. This includes the recognition of the importance of personalized
medicine and the potential of microbiome analysis to inform tailored treatment
approaches, encouraging the development of products that address specific
health needs. Programs such as the FDA’s Breakthrough Devices Program offer
expedited review pathways for innovative diagnostic products that meet unmet
medical needs. This regulatory support enables companies to bring their
microbiome diagnostics to market more rapidly, fostering a competitive
environment that drives growth.
Recent Developments
- In
July 2024- Recent research has revealed a significant connection between the
gut microbiome and autism spectrum disorder (ASD), suggesting potential new
avenues for diagnostics and treatment. The study highlights that gut health may
play a crucial role in influencing ASD, opening the door to innovative
therapeutic strategies. Autism is characterized by developmental challenges
that affect socialization, with common symptoms including difficulties with eye
contact, communication, and social interaction, as well as sensory
sensitivities and repetitive behaviors. Children with autism often face
heightened stress due to everyday tasks and may struggle to articulate their
distress, leading to anxiety and disruptive behaviors. This emerging link
between the gut microbiome and autism underscores the potential for developing
targeted interventions that address both gut health and behavioral symptoms.
- In
October 2023, Clinical Microbiomics A/S, a Copenhagen-based leader in
bioinformatics and systems biology for microbiome research, has announced a
merger with CosmosID Inc., a prominent CLIA-certified and GxP-compliant
microbiome contract research organization (CRO) located in Germantown,
Maryland. This merger will create the
first microbiome service company with a comprehensive global infrastructure,
featuring state-of-the-art multi-omics laboratories, advanced bioinformatics,
applied AI, and integrative systems biology expertise in compliance with GxP
standards. The newly formed entity aims to assist scientists globally in
understanding the microbiome's impact on health and well-being across various
domains, including humans, animals, plants, and the environment.
- In
March 2023, The FDA's approval of Ferring's REBOTYA, the first microbiome
therapy for patients with recurrent C. difficile infections, marks a
significant milestone in the industry, generating considerable excitement. This
approval is expected to pave the way for future microbiome therapies, with
Seres Therapeutics anticipating the FDA's approval of its own product, SER-109,
soon.
Key Market Players
- DNA
Genotek Inc
- Microba
Pty Limited
- Genetic
Analysis AS
- Illumina,
Inc
- Becton,
Dickinson and Company
- BioMe
Oxford Ltd
- Viome
Life Sciences, Inc
- GoodGut
S.L.U.
- Sun
Genomics
- Origin
Sciences
|
By
Product
|
By
Technology
|
By
Application
|
By
End User
|
By
Region
|
- Reagents
& Kits
- Instruments
|
- 16S
rRNA Sequencing
- Shot
Gun Metagenomics
- Meta
transcriptomics
- Others
|
- Disease
Diagnostics Application
- Research
Application
|
- Hospitals
- Academics
and Research Institutes
- Biotechnology
and Pharmaceutical Companies
|
- North
America
- Europe
- Asia
Pacific
- South
America
- Middle
East & Africa
|
Report Scope:
In this report, the Global Microbiome Diagnostics
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Microbiome Diagnostics Market, By Product:
o Reagents & Kits
o Instruments
- Microbiome Diagnostics Market, By Technology:
o 16S rRNA Sequencing
o Shot Gun Metagenomics
o Meta transcriptomics
o Others
- Microbiome Diagnostics Market, By Application:
o Disease Diagnostics
Application
o Research Application
- Microbiome Diagnostics Market, By End User:
o Hospitals
o Academics and Research
Institutes
o Biotechnology and
Pharmaceutical Companies
- Microbiome Diagnostics Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Microbiome
Diagnostics Market.
Available Customizations:
Global Microbiome Diagnostics market report
with the given market data, TechSci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Microbiome
Diagnostics Market is an upcoming report to be released soon. If you wish an
early delivery of this report or want to confirm the date of release, please
contact us at [email protected]